„Novel molecular biological markers of preeclampsia”
Alasztics Bálint
Rácz Károly Klinikai Orvostudományi
Dr. Reusz György
SE Szülészeti és Nőgyógyászati Klinika Baross utcai Részleg
2023-09-28 15:00:00
Reproduktív medicina
Dr. Rigó János
Dr. Rigó János
Dr. Nagy Gyula Richárd
Dr. Halmos Amrita Cecilia
Prof. Dr. Járai Zoltán
Dr. Szigeti Zsanett Judit
Dr. Szánthó András
My doctoral thesis is based on two case-control studies, which aimed to investigate novel platelet biomarkers and oxidative stress biomarkers of preeclampsia.
I confirmed the reduction in platelet count and the increased ratio of activated platelets in the preeclamptic group, consistent with previous reports. Notably, my findings revealed significantly elevated quantities of tissue factor-positive, thrombogenic platelet-derived extracellular vesicles in the plasma of preeclamptic women compared to healthy controls. These observations suggest a shift towards a procoagulant state in preeclampsia, potentially leading to thromboembolic complications. Additionally, I observed lower levels of CD41a and CD62P-positive platelet-derived extracellular vesicles in preeclamptic patients, indicating increased aggregate formation. Although not significantly elevated, my study also noted higher expression of CD63 in preeclamptic patients' platelet-derived extracellular vesicles.
In relation to oxidative stress biomarkers, my investigation focused on the peroxiredoxin-thioredoxin system. I confirmed elevated levels of advanced oxidation protein products (AOPP) in plasma samples of preeclamptic women, indicating a higher level of oxidative stress. Furthermore, I observed an increased ratio of exofacially expressed PRDX1 and TRX1 in lymphocytes and monocytes of preeclamptic women, suggesting that the upregulation of the peroxiredoxin-thioredoxin system in these immune cells may represent a protective response against oxidative stress in preeclampsia.
In addition, my study revealed a negative correlation between the percentage of lymphocytes and monocytes expressing PRDX1 and TRX1 and the birth weight of newborns, particularly in pregnancies complicated by intrauterine growth restriction (IUGR). This finding suggests a higher burden of oxidative stress in cases of IUGR and highlights a compensatory effect of these antioxidant regulatory enzymes. Moreover, I propose that a ratio of PRDX1-expressing lymphocytes below 50% could potentially serve as a useful indicator for ruling out IUGR. These findings not only enhance our present understanding of the condition but also hold the potential to open new fields for research in the realm of maternal-fetal medicine.
